You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • OP0217 Ustekinumab is superior to TNF inhibitor treatment in resolving enthesitis in PSA patients with active enthesitis- results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study

Article info

Article menu

Download PDFPDF

Oral Presentations
PsA: the options grow!
OP0217 Ustekinumab is superior to TNF inhibitor treatment in resolving enthesitis in PSA patients with active enthesitis- results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study
Free

Authors

Citation

Araujo E, Englbrecht M, Hoepken S, et al
OP0217 Ustekinumab is superior to TNF inhibitor treatment in resolving enthesitis in PSA patients with active enthesitis- results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study
Annals of the Rheumatic Diseases 2017;76:142.

Publication history

  • First published June 15, 2017.
Online issue publication 
January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions